IRIS Institutional Research Information System - OPENBS Open Archive UniBS

RAVAGGI, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.184
EU - Europa 2.721
AS - Asia 2.357
SA - Sud America 394
AF - Africa 45
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 9
AN - Antartide 1
Totale 11.720
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.030
CN - Cina 846
SG - Singapore 764
PL - Polonia 590
DE - Germania 510
UA - Ucraina 424
BR - Brasile 350
IT - Italia 335
HK - Hong Kong 287
GB - Regno Unito 216
FI - Finlandia 205
VN - Vietnam 128
CA - Canada 110
RU - Federazione Russa 93
TR - Turchia 89
IE - Irlanda 86
IN - India 60
FR - Francia 55
EE - Estonia 46
BD - Bangladesh 42
SE - Svezia 40
MX - Messico 27
ID - Indonesia 26
AR - Argentina 23
NL - Olanda 22
ZA - Sudafrica 20
ES - Italia 18
AT - Austria 16
BE - Belgio 15
JP - Giappone 15
CZ - Repubblica Ceca 14
LT - Lituania 14
IQ - Iraq 13
KG - Kirghizistan 10
AE - Emirati Arabi Uniti 9
EU - Europa 9
SA - Arabia Saudita 8
AU - Australia 7
BG - Bulgaria 7
KR - Corea 7
JO - Giordania 6
MA - Marocco 6
PK - Pakistan 6
VE - Venezuela 6
TN - Tunisia 5
UZ - Uzbekistan 5
EC - Ecuador 4
IL - Israele 4
IR - Iran 4
LK - Sri Lanka 4
MU - Mauritius 4
NI - Nicaragua 4
NP - Nepal 4
TW - Taiwan 4
AZ - Azerbaigian 3
BB - Barbados 3
CO - Colombia 3
CR - Costa Rica 3
EG - Egitto 3
KZ - Kazakistan 3
PT - Portogallo 3
AL - Albania 2
BY - Bielorussia 2
CL - Cile 2
JM - Giamaica 2
KE - Kenya 2
LU - Lussemburgo 2
LV - Lettonia 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
UY - Uruguay 2
AM - Armenia 1
AQ - Antartide 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
DZ - Algeria 1
ET - Etiopia 1
GD - Grenada 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PY - Paraguay 1
SN - Senegal 1
TJ - Tagikistan 1
TO - Tonga 1
TT - Trinidad e Tobago 1
Totale 11.720
Salva come PNG Salva come JPEG
Città #
Fairfield 744
Warsaw 587
Woodbridge 563
Ashburn 549
Houston 392
Singapore 388
Seattle 333
Jacksonville 307
Chandler 292
Hong Kong 266
Wilmington 263
Ann Arbor 256
Cambridge 250
New York 207
Beijing 182
Dearborn 161
Munich 158
Princeton 149
Los Angeles 135
Helsinki 131
Nanjing 102
Dublin 86
Mcallen 83
Brescia 75
Istanbul 73
Des Moines 59
Shanghai 57
The Dalles 53
Tallinn 46
Dallas 43
Nanchang 42
San Francisco 42
Montréal 39
São Paulo 39
Buffalo 38
Shenyang 37
Dong Ket 36
Milan 36
Moscow 36
Toronto 36
Jinan 33
San Diego 32
Ho Chi Minh City 31
Chicago 30
London 28
Redondo Beach 27
Hebei 26
Changsha 25
Jiaxing 24
Kunming 24
Tianjin 23
Hanoi 21
Denver 20
Montreal 20
Santa Clara 20
Jakarta 18
Turku 18
Guangzhou 17
Hangzhou 17
Rome 16
Chennai 15
Phoenix 15
Brussels 14
Belo Horizonte 13
Central 13
Johannesburg 13
Mexico City 13
Monmouth Junction 13
Tokyo 13
Zhengzhou 13
Nuremberg 12
Stockholm 12
Hefei 11
Paris 11
Bishkek 10
Charlotte 10
Rio de Janeiro 10
Vienna 10
Boston 9
Brooklyn 9
Manchester 9
Ningbo 9
Poplar 9
Ankara 8
Lancaster 8
Lanzhou 8
Leawood 8
Norwalk 8
Orem 8
Taiyuan 8
Taizhou 8
Verona 8
Amsterdam 7
Brno 7
Curitiba 7
Falkenstein 7
Kilburn 7
Mumbai 7
Augusta 6
Campinas 6
Totale 8.233
Salva come PNG Salva come JPEG
Nome #
Influence of maternal CD4+ levels on the predictive value of virus load mother-to-child transmission of HIV type 1 (HIV-1) 405
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 326
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 311
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 309
Claudin3 is localized outside the tight junctions in human carcinomas 272
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 264
A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment 212
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 202
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 196
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 191
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. 189
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 187
Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer 185
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 183
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 180
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 176
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 174
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 172
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 170
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 166
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 166
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 166
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 165
Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways 164
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 162
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 161
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 161
DEVELOPMENT AND THERAPEUTIC EFFECT OF ADOPTIVELY TRANSFERRED T CELLS PRIMED BY TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ENDOMETRIAL CANCER. 159
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 157
Mammaglobin B expression in human endometrial cancer 152
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 151
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 151
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 149
TUMOR-INFILTRATING LYMPHOCYTES CONTAIN HIGHER NUMBERS OF TYPE 1 CYTOKINE EXPRESSORS AND DR+ T CELLS COMPARED WITH LYMPHOCYTES FROM TUMOR DRAINING LYMPH NODES AND PERIPHERAL BLOOD IN PATIENTS WITH CANCER OF THE UTERINE CERVIX. 146
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy 143
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. 140
Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma 140
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial 139
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer 136
IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8 CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER. 135
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines 134
INDUCTION OF OVARIAN TUMOR-SPECIFIC CD CYTOTOXIC T LYMPHOCYTES BY ACID-ELUTED PEPTIDE-PULSED AUTOLOGOUS DENDRITIC CELLS 132
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers 132
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 131
INCREASED LEVELS OF INTERLEUKIN-10 AND TRANSFORMING GROWTH FACTOR-BETA IN THE PLASMA AND ASCITIC FLUID OF PATIENTS WITH ADVANCED OVARIAN CANCER. 128
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. 125
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 124
Claudin-7 expression in human epithelial ovarian cancer 124
Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates 123
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 123
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 122
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro 121
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF TUMOR-INFILTRATING LYMPHOCYTES COMPARED WITH TUMOR-ASSOCIATED LYMPHOCYTES FROM ASCITIC FLUID AND PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH ADVANCED OVARIAN CANCER. 119
Genetic evolution of the hypervariable region 1 in hetpatitis C virus carriers with normal aminotransferase activities 117
EXPRESSION PATTERN AND MOLECULAR FUNCTION OF TRASCRIPTION FACTOR FOXM1 (FORKHEAD BOX PROTEIN M1) IN EPITHELIAL OVARIAN CANCER CLINICAL SPECIMENS AND CELL LINES 116
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 116
Radiation-Enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma 113
Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship 113
Gene expression profiling of olfactory neuroblastoma helps identify prognostic pathways and define potentially therapeutic targets 113
Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. 107
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. 106
DEVELOPMENT, CHARACTERIZATION AND DISTRIBUTION OF ADOPTIVELY TRANSFERRED PERIPHERAL BLOOD LYMPHOCYTES PRIMED BY HUMAN PAPILLOMAVIRUS 18 E7--PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ADENOCARCINOMA OF THE UTERINE CERVIX. 103
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 99
EXPRESSION OF CD56 BY HUMAN PAPILLOMAVIRUS E7-SPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTES CORRELATES WITH INCREASED INTRACELLULAR PERFORIN EXPRESSION AND ENHANCED CYTOTOXICITY AGAINST HLA-A2-MATCHED CERVICAL TUMOR CELLS. 97
Integrated mutational landscape analysis of uterine leiomyosarcomas 95
HE4 and epithelial ovarian cancer : Comparison and clinical evaluation of two immunoassays and a combination algorithm 95
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 90
Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti-Trop-2 Monoclonal Antibody 88
The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features 88
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma 87
Functional profiles of curatively treated adenoid cystic carcinoma unveil prognostic features and potentially targetable pathways 84
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 83
Serum S100A6 concentration predicts peritoneal tumor burden inmice with epithelial ovarian cancer and is associated with advanced stage in patients. 78
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes 75
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study 75
Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer 69
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: A retrospective study 67
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy 62
Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 61
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 56
HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study 49
The Oxford Classic can identify HGSOC patients who may benefit from EMT-targeting therapies 48
Finding the junction between claudins and endometrial carcinoma 46
VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients 45
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine 42
Circulating Serum Micro-RNA as Non-Invasive Diagnostic Biomarkers of Endometriosis 40
Mammaglobin B (SCGB2A1) is a novel tumor antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy 34
Development of a diagnostic model based on serum microRNAs for the diagnosis of endometriosis 17
Totale 11.925
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.308
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.308
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021931 0 0 0 0 0 142 73 156 147 212 123 78
2021/2022772 93 121 10 15 5 48 49 39 32 132 64 164
2022/2023791 130 40 37 51 64 173 10 89 113 9 41 34
2023/2024956 49 32 93 86 47 221 53 49 163 51 15 97
2024/20251.692 18 46 21 281 147 171 104 62 165 103 356 218
2025/20261.976 374 346 255 529 439 33 0 0 0 0 0 0
Totale 11.925